It was observed that both antibodies could effectively clear HPA-1a–positive murine platelets from the circulation and prevent the occurrence of alloimmunization (determined by the presence of antibodies reactive against APLDQ platelets).

Source: https://seekingalpha.com/article/4587538-rallybio-corp-early-stage-developer-with-proof-of-concept-data?source=feed_all_articles

Since mice have a different repertoire of antibodies than humans, murine mAbs have the potential for neutralizing a broader spectrum of SARS-CoV-2 variants than fully human mAbs.

Source: https://forextv.com/top-news/tonix-pharmaceuticals-announces-exclusive-license-of-potential-therapeutic-or-preventative-fully-human-and-murine-anti-sars-cov-2-monoclonal-antibodies/